News & Updates

The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.

People with irritable bowel syndrome (IBS) are not at increased overall risk of cancer relative to the general population, reveals a study. On the contrary, those with IBS appear to have a lower risk of incident colorectal cancer (CRC) and cancer-specific mortality.

Helicobacter pylori eradication treatment leads to large reductions in the risk of gastric cancer and lower rates of associated deaths over 10 years of follow-up, according to a recent meta-analysis.

Treatment with tenapanor improves symptoms in patients with irritable bowel syndrome with constipation (IBS-C) as early as week 1 of treatment, according to two phase III studies presented at DDW 2022.

Antibiotic use appears to be harmful for older adults, with a recent study showing that regardless of class, the drugs raise the risk of developing inflammatory bowel disease (IBD).

Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.

Following discontinuation of nucleot(s)ide analogue therapy, only about one-third of patients with HBeAg-negative chronic hepatitis B (CHB) achieve disease remission, with rare HBsAg loss, as reported in a study. The likelihood of HBsAg loss and disease remission is high in the presence of very low HBsAg levels at baseline.

Use of statins results in reduced all-cause mortality in nearly 30,000 veterans with colorectal cancer (CRC), results of a study have shown.